Viking Therapeutics, Inc.
VKTX
$33.80
-$0.64-1.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -534.80M | -472.34M | -359.64M | -237.39M | -171.55M |
| Total Depreciation and Amortization | 450.00K | 405.00K | 431.00K | 447.00K | 420.00K |
| Total Amortization of Deferred Charges | 8.00K | 32.00K | 56.00K | 80.00K | 96.00K |
| Total Other Non-Cash Items | 31.48M | 32.31M | 31.49M | 26.34M | 24.93M |
| Change in Net Operating Assets | 84.42M | 99.26M | 48.98M | -14.05M | -6.43M |
| Cash from Operations | -418.44M | -340.33M | -278.69M | -224.58M | -152.54M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 399.26M | 332.33M | 341.39M | 272.36M | 138.24M |
| Cash from Investing | 399.26M | 332.33M | 341.39M | 272.36M | 138.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 111.25M | 88.17M | 76.44M | 2.34M | 4.38M |
| Repurchase of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 111.25M | 88.17M | 76.44M | 2.34M | 4.38M |
| Foreign Exchange rate Adjustments | 19.00K | 7.00K | -8.00K | -91.00K | -114.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.08M | 80.18M | 139.13M | 50.03M | -10.04M |